Physician profile
Aaron S Katzenmeyer
NPI 1538454236
$12,245.53
in general payments reported to CMS, 2019-2025
54 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,423 · 2022: $3,499 · 2023: $1,585 · 2024: $1,739 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,324.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,480.86 | 2021-2025 | |
| Novo Nordisk INC | $808.25 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $807.51 | 2021-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $739.18 | 2021-2025 | Trintellix |
| Pfizer INC. | $723.76 | 2021-2025 | |
| Lilly USA, LLC | $690.69 | 2021-2025 | Zepbound, Jardiance, Emgality |
| Amgen INC. | $683.74 | 2021-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $562.51 | 2021-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $494.21 | 2021-2023 | Spravato |
| Axsome Therapeutics, INC. | $331.71 | 2023-2025 | Auvelity, Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.38 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $289.30 | 2021-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $266.78 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $254.12 | 2021 | |
| Eisai INC. | $220.44 | 2021 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $214.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $188.63 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $158.49 | 2021-2025 | Rexulti |
| Tris Pharma INC | $158.26 | 2023-2025 | Dyanavel Xr |
| Esperion Therapeutics, INC. | $141.83 | 2021-2022 | |
| Glaxosmithkline, LLC. | $131.17 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $128.49 | 2024-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.12 | 2024-2025 | Caplyta |
| Lundbeck LLC | $101.93 | 2022-2025 | Rexulti, Vyepti |
| Si-Bone, INC. | $95.45 | 2025 | |
| Shield Therapeutics INC | $87.15 | 2023-2024 | Accrufer |
| Sumitomo Pharma America, INC. | $83.38 | 2023-2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $79.81 | 2021-2022 | |
| Inspire Medical Systems, INC. | $79.56 | 2024-2025 | Inspire |
| Antares Pharma, INC. | $70.89 | 2024-2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $70.56 | 2024-2025 | Quviviq, Quviviq |
| Daiichi Sankyo INC. | $66.04 | 2021 | |
| Medtronic, INC. | $58.40 | 2021-2025 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $57.03 | 2021-2025 | Zoryve |
| Ardelyx, INC. | $52.03 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $44.16 | 2022-2023 | Verquvo, Lagevrio, Belsomra |
| Ironwood Pharmaceuticals, INC | $36.29 | 2022-2023 | Linzess |
| Arbor Pharmaceuticals, INC. | $34.34 | 2021 | |
| Amneal Pharmaceuticals LLC | $27.44 | 2023 | Unithroid |
| E.R. Squibb & Sons, L.L.C. | $27.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.61 | 2021 | |
| Mylan Specialty L.P. | $26.10 | 2022 | |
| Genentech USA, INC. | $25.48 | 2021 | |
| Neos Therapeutics, LP | $23.92 | 2024 | Adzenys Xr-Odt |
| Tolmar, INC. | $20.97 | 2024 | |
| Exact Sciences Corporation | $20.04 | 2023 | Cologuard Collection Kit |
| Axonics, INC. | $18.66 | 2022 | |
| Ibsa Pharma INC. | $18.05 | 2023 | Tirosint, Licart |
| Currax Pharmaceuticals LLC | $17.87 | 2023 | Contrave |
| Hikma Pharmaceuticals USA | $16.77 | 2022 | |
| Inari Medical, INC. | $16.39 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Phathom Pharmaceuticals, INC. | $14.67 | 2025 | Voquezna |
| Bausch Health US, LLC | $14.14 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.87 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Katzenmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.